Amanda Przespolewski, DO, and Ibrahim Aldoss, MD define and discuss how to diagnose patients with Ph+ALL.
Back
Post-Conference Perspectives: Advances in the Management of Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia
Updates in Philadelphia-positive acute lymphoblastic leukemia treatment are highlighted following ASCO 2023.
Post-Conference Perspectives: Advances in the Management of Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia
Episodes
All
All
Drs Aldoss and Przespolewski evaluate the changing treatment landscape for patients diagnosed with Ph+ ALL.
Medical experts highlight recent findings from the PhALLCON study.
Dr Aldoss discusses the role ponatinib and blinatumomab in the management of Ph+ALL.
Key advances in ALL treatment from ASCO 2023 are discussed by Dr Przespolewski.
With their final thoughts, medical experts share unmet needs in the treatment landscape of Ph+ acute lymphoblastic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for PSMA+ mHSPC
2
European Commission Approves First-Line Dato-DXd for Immunotherapy-Ineligible Metastatic TNBC
3
FDA sNDA Submission Is Planned for Selinexor Plus Ruxolitinib in Myelofibrosis
4
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
5